Ceftaroline potency among 9 US Census regions: Report from the 2010 AWARE program

Clinical Infectious Diseases

Volumn 55, Issue SUPPL. 3, 2012, Pages

  Flamm, Robert K ^a   Sader, Helio S ^a   Farrell, David J ^a   Jones, Ronald N ^a,b  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAROLINE; CEFTRIAXONE; CLINDAMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; LINEZOLID; OXACILLIN; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL SKIN DISEASE; BACTERIUM ISOLATE; COAGULASE NEGATIVE STAPHYLOCOCCUS; COMMUNITY ACQUIRED PNEUMONIA; DRUG POTENCY; ENTEROBACTERIACEAE; HAEMOPHILUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; PRIORITY JOURNAL; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS;

ANTI-BACTERIAL AGENTS; BACTERIA; CEPHALOSPORINS; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; UNITED STATES;

EID: 84865271673     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis562     Document Type: Article

References (34)

1. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1-12.
2. Falagas ME, Bliziotis IA. Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era? Int J Antimicrob Agents 2007; 29:630-6.
3. Giske CG, Monnet DL, Cars O, Carmeli Y. Clinical and economic impact of common multidrug-resistant Gram-negative bacilli. Antimi-crob Agents Chemother 2008; 52:813-21.
4. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enter-obacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 2007; 60:913-20.
5. Blot S, Depuydt P, Vandewoude K, De Bacquer D. Measuring the impact of multidrug resistance in nosocomial infection. Curr Opin Infect Dis 2007; 20:391-6.
6. Shorr AF, Tabak YP, Gupta V, Johannes RS, Liu LZ, Kollef MH. Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia. Crit Care 2006; 10: R97.
7. Lye DC, Earnest A, Ling ML, et al. The impact of multidrug resistance in healthcare-associated and nosocomial Gram-negative bacteraemia on mortality and length of stay: cohort study. Clin Microbiol Infect 2012; 18:502-8.
8. Shorr AF. Epidemiology of staphylococcal resistance. Clin Infect Dis 2007; 45(Suppl 3):S171-6.
9. Klevens RM, Edwards JR, Tenover FC, McDonald LC, Horan T, Gaynes R. Changes in the epidemiology of methicillin-resistant Staph-ylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin Infect Dis 2006; 42:389-91.
10. Kock R, Becker K, Cookson B, et al. Methicillin-resistant Staphylococ-cus aureus (MRSA): burden of disease and control challenges in Europe. Euro Surveill 2010; 15:19688.
11. Boucher HW, Corey GR. Epidemiology of methicillin-resistant Staph-ylococcus aureus. Clin Infect Dis 2008; 46(Suppl 5):S344-9.
12. Kosowska-Shick K, McGhee PL, Appelbaum PC. Affinity of ceftaro-line and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother 2010; 54:1670-6.
13. Kosowska-Shick K, McGhee P, Appelbaum PC. Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneu-mococci with various beta-lactam susceptibilities. Antimicrob Agents Chemother 2009; 53:2176-80.
14. Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multi-drug-resistant infection. J Antimicrob Chemother 2010; 65:1119-25.
15. Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbape-nems: past, present, and future. Antimicrob Agents Chemother 2011; 55:4943-60.
16. Perez F, Endimiani A, Ray AJ, et al. Carbapenem-resistant Acineto-bacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination. J Antimicrob Chemother 2010; 65:1807-18.
17. Urban C, Bradford PA, Tuckman M, et al. Carbapenem-resistant Es-cherichia coli harboring Klebsiella pneumoniae carbapenemase beta-lactamases associated with long-term care facilities. Clin Infect Dis 2008; 46:e127-30.
18. McCaig LF, McDonald LC, Mandal S, Jernigan DB. Staphylococcus aureus-associated skin and soft tissue infections in ambulatory care. Emerg Infect Dis 2006; 12:1715-23.
19. Corey GR, Wilcox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vanco-mycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010; 51:641-50.
20. Jones RN, Mendes RE, Sader HS. Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study. J Antimicrob Chemo-ther 2010; 65(Suppl 4):iv17-31.
21. Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 2008; 46:647-55.
22. Corey GR, Wilcox MH, Talbot GH. CANVAS 1: the first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010; 65(Suppl 4):iv41-51.
23. Sader HS, Fritsche TR, Jones RN. Antimicrobial activities of ceftaro-line and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus. Antimicrob Agents Che-mother 2008; 52:1153-5.
24. File TM Jr, Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 2010; 51:1395-405.
25. File TM Jr, Low DE, Eckburg PB, et al. FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011; 66(Suppl 3):iii19-32.
26. Jones RN, Farrell DJ, Mendes RE, Sader HS. Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study. J Antimi-crob Chemother 2011; 66(Suppl 3):iii69-80.
27. Jones RN, Fritsche TR, Ge Y, Kaniga K, Sader HS. Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests. J Antimicrob Chemother 2005; 56: 1047-52.
28. Flamm RK, Sader HS, Farrell DJ, Jones RN. Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance Program. Antimicrob Agents Chemother 2012; 56:2933-40.
29. Forest Laboratories, Inc. Teflaro. Package Insert. Revised May 2012. Available at: http://www.frx.com/pi/Teflaro-pi.pdf. Accessed 27 June 2012.
30. Clinical and Laboratory Standards Institute. M07-A9. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobi-cally; approved standard: 9th ed. Wayne, PA: Clinical and Laboratory Standards Institute, 2012.
31. Clinical and Laboratory Standards Institute. M100-S22. Performance standards for antimicrobial susceptibility testing: 22nd informational supplement. Wayne, PA: Clinical and Laboratory Standards Institute, 2012.
32. Clinical and Laboratory Standards Institute. M45-A2. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria. Wayne, PA: Clinical and Laboratory Standards Institute, 2010.
33. Tygacil. Package Insert. Revised January 2011. Available at: http:///www.tygacil.com. Accessed 27 June 2012.
34. Infectious Diseases Society of America. The 10 × '20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 2010; 15:1081-3.